TLC 388 is a DNA topoisomerase I inhibitor potentially for the treatment of Renal carcinoma and Hepatocellular carcinoma References: Ghamande S, Lin CC, Cho DC, Shapiro GI, Kwak EL, Silverman MH, Tseng Y, Kuo MW, Mach WB, Hsu SC, Coleman T, Yang JC, Cheng AL, Ghalib MH, Chuadhary I, Goel S. A phase 1 open-label, sequential dose-escalation study investigating the safety, tolerability, and pharmacokinetics of intravenous TLC388 administered to patients with advanced solid tumors. Invest New Drugs. 2014 Jun;32(3):445-51. doi: 10.1007/s10637-013-0044-7. PubMed PMID: 24271274.

纯度：≥98%

CAS：1432468-79-5